Aims to offer behavioral insights and diverse patient perspectives spanning the product development lifecycle
Syneos Health, a biopharma clinical and commercial solutions organization, has launched its Patient Voice Consortium. The consortium is a cross-functional hub designed to share expertise, resources and relationships to enable integration of patient perspectives across the product lifecycle. Vehicles to accomplish this will include therapeutic, patient-reported outcomes and registries, patient support, storytelling, behavioral science, compliance and health policy capabilities.
According to Syneos, the recognition of the “patient voice” as a vital component of product development is increasing, based on recent advocacy and regulatory efforts, such as FDA’s Patient-Focused Drug Development initiative. These efforts, which are alluded to in the first episode of The Pharmaceutical Commerce Podcast, aim to define the best practices for gaining patient insight to pressure test, problem solve and co-create clinical trial design, communications, stakeholder education, access initiatives and launch strategies.
“Our consortium brings together, in a more formalized structure, what has been a long-standing, existing patient knowledge base at Syneos Health. We’re securing insights—in inclusive ways across the product development lifecycle,” says Nick Kenny, Syneos chief scientific officer. “In a world where patient perspectives should be at the forefront of innovation, the consortium addresses longstanding operational barriers and paves new and more informed ways forward. At the heart of the Patient Voice Consortium is our diversity, equity and inclusion [DE&I] focus, as we strive to eliminate disparities in healthcare. Our goal is to speak fluent 'Lab to Life’ to improve patient outcomes.”
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
Study Connects COVID-19 Treatment Disparities to Gaps in Testing and Virtual Access
July 11th 2025New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem from encounter-level care barriers, such as limited access to rapid tests and telehealth, which emphasizes the need for systemic and practice-level reforms.